These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 3126272

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
    Ogawa N, Yamamoto M, Takayama H.
    J Med; 1985; 16(5-6):525-34. PubMed ID: 3938472
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.
    Suzuki T, Sakoda S, Ueji M, Kishimoto S, Hayashi A, Kondo T, Narabayashi H.
    Neurology; 1984 Nov; 34(11):1446-50. PubMed ID: 6436731
    [Abstract] [Full Text] [Related]

  • 7. [D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson's disease or pure akinesia].
    Kondo T.
    Rinsho Shinkeigaku; 1984 Mar; 24(3):280-8. PubMed ID: 6432393
    [No Abstract] [Full Text] [Related]

  • 8. Effective treatment of pure akinesia with L-threo-3,4-dihydroxyphenylserine (DOPS): report of a case, with pharmacological considerations.
    Yamamoto M, Ujike H, Ogawa N.
    Clin Neuropharmacol; 1985 Mar; 8(4):334-42. PubMed ID: 2416437
    [Abstract] [Full Text] [Related]

  • 9. L-threo-3,4-dihydroxyphenylserine treatment for gait apraxia in parkinsonian patients.
    Yoshida M, Noguchi S, Kuramoto S.
    Kurume Med J; 1989 Mar; 36(2):67-74. PubMed ID: 2511378
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease.
    Fukada K, Endo T, Yokoe M, Hamasaki T, Hazama T, Sakoda S.
    Med Hypotheses; 2013 Feb; 80(2):209-12. PubMed ID: 23265352
    [Abstract] [Full Text] [Related]

  • 13. Mass spectrometric measurements of norepinephrine synthesis in man from infusion of stable isotope-labelled L-threo-3,4-dihydroxyphenylserine.
    Suzuki T, Sakoda S, Ueji M, Kishimoto S.
    Life Sci; 1985 Feb 04; 36(5):435-42. PubMed ID: 3918223
    [Abstract] [Full Text] [Related]

  • 14. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients.
    Tohgi H, Abe T, Takahashi S, Takahashi J, Ueno M, Nozaki Y.
    Neurosci Lett; 1990 Aug 14; 116(1-2):194-7. PubMed ID: 2259448
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Studies of neurocirculatory effects of long-term L-threo-3,4-dihydroxyphenylserine administration in a patient with familial amyloidotic polyneuropathy.
    Azuma T, Suzuki T, Mizuno R, Tsujino S, Kishimoto S, Mizuta E, Ichikawa K.
    Acta Neurol Scand; 1988 May 14; 77(5):409-13. PubMed ID: 3137768
    [Abstract] [Full Text] [Related]

  • 20. The effect of L-threo-DOPS on synaptic transmission to soleus motoneuron in normal subjects and patients with Parkinson's disease.
    Nakajima Y, Kagamihara Y, Nagaoka M, Tanaka R.
    Neurosci Res; 1987 Oct 14; 5(1):16-27. PubMed ID: 2829065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.